Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$8.51 - $13.6 $1.98 Million - $3.17 Million
233,000 New
233,000 $2.44 Million
Q2 2022

Aug 15, 2022

SELL
$7.31 - $11.85 $1.18 Million - $1.91 Million
-161,500 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.19 - $9.56 $676,685 - $1.54 Million
161,500 New
161,500 $1.54 Million

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Polar Asset Management Partners Inc. Portfolio

Follow Polar Asset Management Partners Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

News

Stay updated on Polar Asset Management Partners Inc. with notifications on news.